Cargando…

Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort

OBJECTIVE: To evaluate the effect of covid-19 vaccination on the severity of symptoms in patients with long covid. DESIGN: Target trial emulation based on ComPaRe e-cohort. DATA SOURCE: ComPaRe long covid cohort, a nationwide e-cohort (ie, a cohort where recruitment and follow-up are performed onlin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Viet-Thi, Perrodeau, Elodie, Saldanha, Julia, Pane, Isabelle, Ravaud, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978748/
https://www.ncbi.nlm.nih.gov/pubmed/36910458
http://dx.doi.org/10.1136/bmjmed-2022-000229
_version_ 1784899584773849088
author Tran, Viet-Thi
Perrodeau, Elodie
Saldanha, Julia
Pane, Isabelle
Ravaud, Philippe
author_facet Tran, Viet-Thi
Perrodeau, Elodie
Saldanha, Julia
Pane, Isabelle
Ravaud, Philippe
author_sort Tran, Viet-Thi
collection PubMed
description OBJECTIVE: To evaluate the effect of covid-19 vaccination on the severity of symptoms in patients with long covid. DESIGN: Target trial emulation based on ComPaRe e-cohort. DATA SOURCE: ComPaRe long covid cohort, a nationwide e-cohort (ie, a cohort where recruitment and follow-up are performed online) of patients with long covid, in France. METHODS: Adult patients (aged ≥18 years) enrolled in the ComPaRe cohort before 1 May 2021 were included in the study if they reported a confirmed or suspected SARS-CoV-2 infection, symptoms persistent for >3 weeks after onset, and at least one symptom attributable to long covid at baseline. Patients who received a first covid-19 vaccine injection were matched with an unvaccinated control group in a 1:1 ratio according to their propensity scores. Number of long covid symptoms, rate of complete remission of long covid, and proportion of patients reporting an unacceptable symptom state at 120 days were recorded. RESULTS: 910 patients were included in the analyses (455 in the vaccinated group and 455 in the control group). By 120 days, vaccination had reduced the number of long covid symptoms (mean 13.0 (standard deviation 9.4) in the vaccinated group v 14.8 (9.8) in the control group; mean difference −1.8, 95% confidence interval −3.0 to −0.5) and doubled the rate of patients in remission (16.6% v 7.5%, hazard ratio 1.93, 95% confidence interval 1.18 to 3.14). Vaccination reduced the effect of long covid on patients' lives (mean score on the impact tool 24.3 (standard deviation 16.7) v 27.6 (16.7); mean difference −3.3, 95% confidence interval −5.7 to −1.0) and the proportion of patients with an unacceptable symptom state (38.9% v 46.4%, risk difference −7.4%, 95% confidence interval −14.5% to −0.3%). In the vaccinated group, two (0.4%) patients reported serious adverse events requiring admission to hospital. CONCLUSION: In this study, covid-19 vaccination reduced the severity of symptoms and the effect of long covid on patients' social, professional, and family lives at 120 days in those with persistent symptoms of infection.
format Online
Article
Text
id pubmed-9978748
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-99787482023-03-08 Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort Tran, Viet-Thi Perrodeau, Elodie Saldanha, Julia Pane, Isabelle Ravaud, Philippe BMJ Med Research OBJECTIVE: To evaluate the effect of covid-19 vaccination on the severity of symptoms in patients with long covid. DESIGN: Target trial emulation based on ComPaRe e-cohort. DATA SOURCE: ComPaRe long covid cohort, a nationwide e-cohort (ie, a cohort where recruitment and follow-up are performed online) of patients with long covid, in France. METHODS: Adult patients (aged ≥18 years) enrolled in the ComPaRe cohort before 1 May 2021 were included in the study if they reported a confirmed or suspected SARS-CoV-2 infection, symptoms persistent for >3 weeks after onset, and at least one symptom attributable to long covid at baseline. Patients who received a first covid-19 vaccine injection were matched with an unvaccinated control group in a 1:1 ratio according to their propensity scores. Number of long covid symptoms, rate of complete remission of long covid, and proportion of patients reporting an unacceptable symptom state at 120 days were recorded. RESULTS: 910 patients were included in the analyses (455 in the vaccinated group and 455 in the control group). By 120 days, vaccination had reduced the number of long covid symptoms (mean 13.0 (standard deviation 9.4) in the vaccinated group v 14.8 (9.8) in the control group; mean difference −1.8, 95% confidence interval −3.0 to −0.5) and doubled the rate of patients in remission (16.6% v 7.5%, hazard ratio 1.93, 95% confidence interval 1.18 to 3.14). Vaccination reduced the effect of long covid on patients' lives (mean score on the impact tool 24.3 (standard deviation 16.7) v 27.6 (16.7); mean difference −3.3, 95% confidence interval −5.7 to −1.0) and the proportion of patients with an unacceptable symptom state (38.9% v 46.4%, risk difference −7.4%, 95% confidence interval −14.5% to −0.3%). In the vaccinated group, two (0.4%) patients reported serious adverse events requiring admission to hospital. CONCLUSION: In this study, covid-19 vaccination reduced the severity of symptoms and the effect of long covid on patients' social, professional, and family lives at 120 days in those with persistent symptoms of infection. BMJ Publishing Group 2023-02-01 /pmc/articles/PMC9978748/ /pubmed/36910458 http://dx.doi.org/10.1136/bmjmed-2022-000229 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Tran, Viet-Thi
Perrodeau, Elodie
Saldanha, Julia
Pane, Isabelle
Ravaud, Philippe
Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort
title Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort
title_full Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort
title_fullStr Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort
title_full_unstemmed Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort
title_short Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort
title_sort efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on compare e-cohort
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978748/
https://www.ncbi.nlm.nih.gov/pubmed/36910458
http://dx.doi.org/10.1136/bmjmed-2022-000229
work_keys_str_mv AT tranvietthi efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort
AT perrodeauelodie efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort
AT saldanhajulia efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort
AT paneisabelle efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort
AT ravaudphilippe efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort